Radiobiology of low-dose-rate radiation relevant to radioimmunotherapy.
Systemically delivered targeted radioisotopes are being used ever-increasingly for cancer therapy. Compared with conventional external beam radiation therapy, the radiation dose-rate associated with these novel systemic therapies is approximately two orders of magnitude lower in intensity (dose-rate). Hence it is referred to as low dose-rate (LDR) radiotherapy. An awareness of the unique radiobiology associated with LDR-based therapy provides a basis for cautious enthusiasm as these new therapies are explored.
Murtha
A D
AD
Department of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. albertmu@cancerboard.ab.ca
D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011836:Radiation Tolerance; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D011879:Radiotherapy Dosage
D019275:Radiopharmaceuticals